Acer Therapeutics — Opexa Therapeutics — Investor Presentation (August 2014)
38 slides from Acer Therapeutics's investor presentation, Aug 14, 2014
Slide 1: Opexa Therapeutics: Precision Immunotherapy
Opexa Therapeutics, Inc. NASDAQ: OPXA Precision Immunotherapy August 2014 The Woodlands, TX Precision Immunotherapy TM
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements• This investor presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in thi
Slide 3: Introduction to Opexa
3 Introduction to Opexa • Antigen specific T-cell immunotherapy platform – Potential to address multiple therapeutic areas – Lower capital intensity by leveraging existing GMP manufacturing – Strong Patent Estate: 50 patents issued on T-cell platform (domestic and international) • Lead Program: Tcel
Slide 4: Progress Update
4 Progress Update • Clinical – As of June 30, 2014, Opexa had completed enrollment and randomized 190 patients in the Abili-T study in SPMS – Top line data expected in 2H 2016 • Financial – As of June 30, 2014, Opexa had $16.2 million in cash and cash equivalents – Projected liquidity into Q4 2015,
Slide 5: Tcelna in Secondary Progressive MS
5 Tcelna in Secondary Progressive MS SPMS 450,000 Individuals in North America diagnosed with MS; 30-45 % potentially have an SPMS diagnosis Market Size: $7 Billion (est.) RRMS, CIS, PPMS • Potential SPMS market in North America alone could exceed $7 billion • Roughly 150,000 SPMS patients in North
Slide 6: The Root Cause of Multiple Sclerosis: Activated T-cells Degrade Myelin
6 The Root Cause of Multiple Sclerosis: Activated T- cells Degrade Myelin and Damage Myelin Producing Cells Adapted by permission from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY 3, 483-492 (June 2003), copyright (2003) Cytokines Damage Damage • In MS patients, the faulty immune system is no
Slide 7: Tcelna Consists of Attenuated Antigen Specific T-cell Clones
7 Tcelna® Consists of Attenuated Antigen Specific T-cell Clones • Therapeutic dose of Tcelna (attenuated T-cell clones) is injected subcutaneously • Immune system recognizes the large volume of cells (30-45 million) under the skin as potential foreign pathogens • We believe Tcelna triggers an immune
Slide 8: Could Address the Root Cause of MS by Preventing Demyelination
Could Address the Root Cause of Multiple Sclerosis by Preventing Demyelination and Enabling Remyelination Adapted by permission from Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY 3, 483-492 (June 2003), copyright (2003) Opexa’s Strategy Tcelna programs the immune system to specifically recogni
Slide 9: Mechanism of Action: Reduction in Myelin Reactive T-Cells
9 Mechanism of Action Reduction in Myelin Reactive T-Cells -100% -90% -80% -70% -60% -50% -40% -30% -20% -10% 0% Week 0 Week 5 Week 13 Week 21 Week 28 Week 52 Results from Tcelna dose ranging studies: Published in Clinical Immunology (2009) 131, 202-215 Reduction in MRTC Dose 2 Dose 3 Dose 4 Each do
Slide 10: Single Cycle Manufacturing Process
10 Single Cycle Manufacturing Process: Annual course of treatment (5 doses) from one blood draw Cryopreservation Formulation/ Irradiation of each dose as required Administration: 5 subcutaneous injections/year Manufacturing and QC Dispensation 35 days Epitope Profiling 1 day 14 days - Red Cross - Bl
Slide 11: Merck Serono Agreement for MS indication
11 Merck Serono Agreement for MS indication • February 2013 option and license agreement with Merck Serono – Up to $220 million in additional payments • Option exercise $25 million for starting Phase III/ or $15 million if another Phase II • $35 million FDA filing, approval and commercialized in US
Slide 12: Tcelna Development Program
12 Tcelna Development Program Broad Spectrum of MS patients treated Phase Completion Dates Population Total N Treatment Duration (months) Tcelna Placebo Baylor 1998 RRMS, PPMS, SPMS (26) 114 Up to 24 months 114 Phase I dose escalation 2006 RRMS (5) SPMS (6) 16 12 16 - Phase I/II Open label retreatme
Slide 13: TERMS Study - Prospective Analysis in More Active or Progressive Patients
13 TERMS Study - Prospective Analysis in More Active or Progressive Patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) 2.4 2.23 2.2 2.39 2.1 2.15 2.2 2.25 2.3 2.35 2.4 2.45 EDSS Score ( Mean) Baseline Week 52 Tcelna Placebo (p=0.045) 0.28 0.63 0
Slide 14: Tcelna Stabilizes Disease in SPMS at 2 Years
14 Tcelna Stabilizes Disease in SPMS at 2 Years 80% 20% 40% 0% 20% 40% 60% 80% 100% Percent of Patients Showing Disease Stabilization Stabilization vs. Historical Progression Stable Progressed 80% of subjects treated with Tcelna showed no further disease progression by EDSS at 2 years Historical Dis
Slide 15: Abili-T: Phase IIb Clinical Trial
15 Abili-T : Phase IIb Clinical Trial • Enrollment completed Q2 2014 – 190 patients randomized • FDA Fast Track Designation • Secondary Progressive MS patient population – EDSS range 3-6; 18-60 years old • Design – Double-blind, 1:1 randomized, placebo-controlled – Approximately 35 clinical sites in
Slide 16: Efficacy Assessments
16 Efficacy Assessments • Primary Endpoint – Whole-brain atrophy • Secondary Endpoints – Sustained progression measured by EDSS – Time to sustained progression – T2 lesions progressing to hypointense lesions (black holes) – Change in EDSS – Annualized Relapse Rate (ARR) – Change in MSFC Assessment o
Slide 17: Immune Monitoring Program
17 Immune Monitoring Program Phenotypical Analysis (CD4 and CD8) Pro-inflammatory Anti-inflammatory TH1 Treg TH17 Tr1 TH2 IL-2 IL-4 IL-6 IL-5 IL-12 IL-10 IL-17E, IL-17F IL-23 IL-27 TNFα TGFβ IFNϒ BDNF Plausible indicators of Tcelna efficacy • Reduction in Th1/TH17 • Increase in Treg/Tr1 cells • Redu
Slide 18: Financials
18 Financials Cash and Cash Equivalents (MM) as of June 30, 2014 $16.2 Shares outstanding (MM) as of June 30, 2014 27.7 Warrants (MM) (1) 3.1 Stock Options (MM) (2) ~2.5 (1) Weighted average exercise price =$4.12 as of June 30, 2014 (2)Weighted average exercise price = $2.96 as of June 30, 2014
Slide 19: Experienced Management Team and Board of Directors
19 Experienced Management Team and Board of Directors Neil Warma, President & CEO, Director 19+ years international healthcare experience with large Pharma and emerging biotechnology companies Former SeniorManagement, Novartis Pharmaceuticals, Basel, Switzerland Former CEO, Viron Therapeutics, Inc.
Slide 20: SPMS Scientific Advisory Board
20 SPMS Scientific Advisory Board Dawn McGuire, M.D., FAAN (Chair) • Advisory Council of the Gill Heart Institute • Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D • Chair of Neurology at Heinrich-Heine University, Düsseldorf • Executive Board member of ECT
Slide 21: Investment Thesis
21 Investment Thesis • T-cell platform company with Fast Track designation in SPMS • Strong Intellectual property with 50 issued patents (domestic and international) • Esteemed Scientific Advisory Board • Precision Immunotherapy potentially optimizes benefit-risk profile • Targeting an unmet medical
Slide 22: Appendix
oe OPEXA THERAPEUTICS APPENDIX
Slide 23: Tcelna Highlights
23 Tcelna® Highlights • Clinical studies conducted in Relapsing Remitting and Secondary Progressive MS • Progress made on manufacturing with focus on commercially viable process ─ Over 850 Tcelna preparations have been successfully manufactured, reproducible and consistent • Safety demonstrated and
Slide 24: Tcelna Manufacturing: Personalization followed by Expansion
24 Tcelna Manufacturing: Personalization followed by Expansion Step The Epitope Profiling Assay (EPA) • Screen peripheral blood for Myelin-Reactive T-cells (MRTCs), and mapping of immunodominant epitopes to MBP, MOG and PLP – 109 overlapping peptides encompassing MBP, MOG and PLP – Interferon gamma
Slide 25: Tcelna Manufacturing: Precision Medicine
25 Year 2 Year 3 Tcelna Manufacturing: Precision Medicine Proprietary Assay Enables Annual Personalized Treatments Year 1 Conduct analysis of 109 peptides from all three key myelin proteins (MBP, MOG, PLP)• Re-assess epitope profile annually to identify epitope shift • Develop newly personalized for
Slide 26: TERMS Study: A Completed Phase IIb Clinical Trial in RRMS
26 • Completed Phase IIb clinical trial in 150 RRMS patients; 33 sites in U.S. • mITT population (n=142) • 37% reduction in ARR vs. placebo • ARR 0.214 vs. 0.339 • Superior safety and promising efficacy trend demonstrated • Two End-of-Phase II meetings with FDA successfully completed 0.214 0.339 0 0
Slide 27: TERMS Study: Safety Overview
27 Safety Summary Deaths • No deaths occurred Serious Adverse Events (SAEs) • No treatment-related SAEs Most common adverse events • Mild to moderate injection site reaction TERMS Study: Safety Overview
Slide 28: TERMS Study - Subgroup Analysis in Patients Naïve to DMT
28 TERMS Study - Subgroup Analysis in Patients Naïve to DMT Annualized relapse rate in DMT naïve populations. ARR in placebo subjects without previous disease modifying treatment (DMT) experience reflects relapse rates commonly seen in other placebo controlled trials in MS. In this subpopulation, tr
Slide 29: Secondary Progressive MS: Overview of Phase I/II Patients
29 • 36 SPMS patients treated in three clinical studies – 35 of these patients were treated with Tcelna for two years – 26 patients treated at Baylor; 10 patients treated by Opexa • Promising efficacy observed – Disease stabilization as measured by EDSS was observed in 80% of patients at two years (
Slide 30: Tcelna Reduces Annualized Relapse Rate in SPMS
30 Tcelna Reduces Annualized Relapse Rate (ARR) in SPMS at 2 years Annualized Relapse Rate ( ARR) 0.00 0.10 0.20 0.30 0.40 0.50 0.60 Baseline 12 Months 24 Months In 21.8 years of cumulative patient follow up, only 1 patient experienced 1 relapse One relapse observed in 21 years of cumulative patient
Slide 31: Tcelna Stabilizes Quality of Life Scores in SPMS
31 Tcelna Stabilizes Quality of Life Scores in SPMS at 2 years 0.9% 1.2% 2.1% 5.1% -6.0% -4.0% -2.0% 0.0% 2.0% 4.0% Physical Psychological 12 Month 18-24 Month Negative percent change indicates improvement from baseline Following two years of treatment, no worsening of physical condition and improve
Slide 32: Efficacy Assessments Schedule
32 Efficacy Assessments EDSS: Expanded Disability Status Scale NEURO: Neurological Examination SDMT: Symbol Digit Modalities Test MSFC: MS Functional Composite MSQLI: MS Quality of Life Indicator MRI: Magnetic Resonance Imaging T 500 mL Procurement Immune Monitoring Tcelna dose Abili-T Annual Treatm
Slide 33: Mechanism of Action
33 Mechanism of Action • Attenuated, patient-specific (autologous) myelin reactive Tcells (MRTC) – MRTC expanded ex vivo in response to immunodominant peptides of MBP, MOG and PLP • Therapeutic sc dosing (30-45 x 106 cells) stimulates host reactivity to the ‘over-represented’ MRTC inducing a dominan
Slide 34: Mechanism of Action: Tcelna increases Tr1 cells in SPMS Patients
34 Mechanism of Action Tcelna increases Tr1 cells in SPMS Patients Clinical findings in Tcelna treated patients • All three patients (who had experienced relapse in preceding 12-24 month) remained relapse free during the 52-week assessment • Showed stabilization of disease progression • Showed a 57%
Slide 35: Mechanism of Action: The Immunopathology of SPMS
35 Mechanism of Action The Immunopathology of SPMS • SPMS is associated with compartmentalized CNS inflammatory cells - Microglia activation suggests ongoing chronic innate immune responses • SPMS is associated with inflammatory processes localized within the central nervous system - Mechanisms resp
Slide 36: Baseline Abili-T patients versus Healthy Individuals
36 Baseline Abili-T patients versus Healthy Individuals CD4+ TR1: CD4+CD45RA-LAG3+CD49b+ % of CD4+ T cells 0 1 2 3 4 ** ** (p=0.01) Healthy Donors SPMS PatientsSPMS subjects have a reduced frequency of IL-10 secreting TR1 cells ACTRIMS 2013 Poster: Profiling of Secondary Progressive MS by Multicolor
Slide 37: SPMS subjects have reduced nTReg cells
37 SPMS subjects have reduced nTReg cells (another type of CD4 cells) Foxp3+ nTregs: CD4+CD127-CD25bright Foxp3+ % of CD4+ T cells 0.0 0.2 0.4 0.6 0.8 1.0 * * (p=0.06) Healthy Donors SPMS Patients Foxp3+ nTregs: CD4+CD127-CD25bright Foxp3+ MFI 0 5000 1000015000 20000 25000 (p= 0.56) Healthy Donors S
Slide 38: SPMS patients have fewer Anti-inflammatory monocytes
38 SPMS patients have fewer Anti-inflammatory monocytes (PDL1 and HLA-G) PD-L1+ Monocytes: CD14+CD16-ICOS+PD-L1+ % of Conv Monocytes 0 2 4 6 ** ** (p=0.004) Healthy Donors SPMS Patients HLA-G+ Monocytes: CD14+CD16-ICOS+HLA-G+ % of Conv Monocytes 0.0 0.5 1.0 1.5 2.0 (p=0.164) Healthy Donors SPMS Pati
Opexa Therapeutics — Investor Presentation (August 2014) on 6ix